VivoSeq
Oncology

Blastic Plasmacytoid Dendritic Cell Neoplasm

19

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Blastic Plasmacytoid Dendritic Cell Neoplasm is an emerging landscape with 19 programs across 11 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Stemline Therapeutics, Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1S

Stemline Therapeutics, Inc.

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

15 of 17 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody16%Cell therapy16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Completed2 · 29%
Terminated1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04216524·40 enrolled
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Recruiting·—·Phase 1·NCT03113643·72 enrolled
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT06006403·36 enrolled
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Active, not recruiting·—·Phase 1·NCT02159495·31 enrolled
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Completed·—·Phase 1·NCT03485547·5 enrolled
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Completed·SStemline Therapeutics, Inc.·Phase 1/2·NCT02113982·138 enrolled
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04317781·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)